Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis

Kidney International

Volumn 81, Issue 4, 2012, Pages 363-369

  Peng, Zhi Yong ^a   Wang, Hong Zhi ^a,b   Carter, Melinda J ^a   Dileo, Morgan V ^a   Bishop, Jeffery V ^a   Zhou, Fei Hu ^a   Wen, Xiao Yan ^a   Rimmelé, Thomas ^a   Singbartl, Kai ^a   Federspiel, William J ^a   Clermont, Gilles ^a   Kellum, John A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

apheresis; cytokines; inflammation mediators; sepsis; sorbents

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; SORBENT; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; APHERESIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; EXCHANGE BLOOD TRANSFUSION; EXTRACORPOREAL BLOOD PURIFICATION; EXTRACORPOREAL CIRCULATION; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; RAT; SEPSIS; SHAM PROCEDURE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 84856456910     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.320     Document Type: Article

References (35)

1. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2002; 29: 1303-1310. (Pubitemid 32641789)
2. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-353. (Pubitemid 43145611)
3. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457-467.
4. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9: 517-524. (Pubitemid 36597096)
5. van der Poll T, Van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13: 413-426. (Pubitemid 29248753)
6. Singer M. The key advance in the treatment of sepsis in the last 10 yearsy doing less. Crit Care 2006; 10: 122.
7. Kellum JA, Kong L, Fink MP, et al., GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the GenIMS study. Arch Intern Med 2007; 167: 1655-1663. (Pubitemid 47280347)
8. Venkataraman R, Subramanian S, Kellum JA. Extracorporeal blood purification in severe sepsis. Crit Care 2003; 7: 139-145. (Pubitemid 36432672)
9. Bellomo R, Kellum JA, Gandhi CR et al. The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000; 161: 1429-1436. (Pubitemid 30329008)
10. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factorkappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004; 32: 801-905.
11. Ito M, Kase H, Shimoyama O et al. Effects of polymyxin B-immobilized fiber using a rat cecal ligation and perforation model. ASAIO J 2009; 55: 246-250.
12. Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008; 36: 1573-1577. (Pubitemid 351620670)
13. Honore PM, Jamez J, Wauthier M et al. Prospective evaluation of shortterm, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28: 3581-3587.
14. Ratanarat R, Brendolan A, Piccinni P et al. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care 2005; 9: R294-R302.
15. Vincent JL, Laterre PF, Cohen J et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400-405. (Pubitemid 40571661)
16. Cole L, Bellomo R, Hart G et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100-106. (Pubitemid 34112184)
17. Payen D, Mateo J, Cavaillon JM et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37: 803-810.
18. HonoréPM, Joannes-Boyau O, Collin V et al. Continuous hemofiltration in 2009: what is new for clinicians regarding pathophysiology, preferred technique and recommended dose? Blood Purif 2009 28 135-143.
19. Ronco C, Brendolan A, Lonnemann G et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002; 30: 1250-1255. (Pubitemid 34620967)
20. Kellum JA. Hemoadsorption therapy for sepsis syndromes. Crit Care Med 2003; 31: 323-324. (Pubitemid 36151201)
21. Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007; 81: 137-143. (Pubitemid 46021262)
22. Neilson D, Kavanagh JP, Rao PN. Kinetics of circulating TNF alpha and TNF soluble receptors following surgery in a clinical model of sepsis. Cytokine 1996; 8: 938-943. (Pubitemid 27091196)
23. Walley KR, Lukacs NW, Standiford TJ et al. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996; 64: 4733-4738. (Pubitemid 26357085)
24. Hubbard WJ, Choudhry M, Schwacha MG et al. Cecal ligation and puncture. Shock 2005; 24(Suppl 1): 52-57.
25. Singleton KD, Wischmeyer PE. Distance of cecum ligated influences mortality, tumor necrosis factor-a and interleukin-6 expression following cecal ligation and puncture in the rat. Eur Surg Res 2003; 35: 486-491. (Pubitemid 37346753)
26. Maier S, Traeger T, Entleutner M et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 2004; 21: 505-511.
27. Peng Z, Singbartl K, Simon P et al. Blood purification in sepsis: a new paradigm. Contrib Nephrol 2010; 165: 322-328.
28. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150. (Pubitemid 36056721)
29. Ronco C, Bonello M, Bordoni V et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004; 22: 164-174. (Pubitemid 38142302)
30. Olsson J, Paulsson J, Dadfar E et al. Monocyte and neutrophil chemotactic activity at the site of interstitial inflammation in patients on high-flux hemodialysis or hemodiafiltration. Blood Purif 2009; 28: 47-52.
31. Yu C, Liu ZH, Chen ZH et al. Improvement of monocyte function and immune homeostasis by high volume continuous venovenous hemofiltration in patients with severe acute pancreatitis. Int J Artif Organs 2008; 31: 882-890.
32. Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006; 72: 1102-1113. (Pubitemid 44468394)
33. Leeson MC, Fujihara Y, Morrison DC. Evidence for lipopolysaccharide as the predominant proinflammatory mediator in supernatants of antibiotic-treated bacteria. Infect Immun 1994; 62: 4975-4980. (Pubitemid 24332804)
34. Szodoray P, Alex P, Brun JG et al. Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004; 59: 592-599. (Pubitemid 38789229)
35. Yamada S, Yakabe K, Ishii J et al. New high mobility group box 1 assay system. Clin Chim Acta 2006; 372: 173-178. (Pubitemid 44286776)